Patents Assigned to Glykon Technologies Group, LLC
-
Patent number: 11957649Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.Type: GrantFiled: May 25, 2021Date of Patent: April 16, 2024Assignee: Glykon Technologies Group, LLCInventor: Daniel E. Clouatre
-
Patent number: 11795187Abstract: Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.Type: GrantFiled: January 20, 2022Date of Patent: October 24, 2023Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Daniel E. Clouatre, Nimpan Bangun, Dallas L. Clouatre
-
Patent number: 11766415Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.Type: GrantFiled: May 25, 2021Date of Patent: September 26, 2023Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventor: Daniel E. Clouatre
-
Patent number: 11744814Abstract: Provided is a method of treating a subject, including: (i) determining an initial level of blood oxygen saturation in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, wherein HCA is (?)-hydroxycitric acid, a salt thereof, or a derivative thereof, thereby increasing blood oxygen saturation. Provided is a kit including HCA and instructions directing a subject to ingest the HCA if the subject is determined to have unhealthily low blood oxygen saturation. Provided is a method of treating a subject, including: (i) determining an initial level of blood hemoglobin in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, thereby increasing blood hemoglobin.Type: GrantFiled: May 25, 2021Date of Patent: September 5, 2023Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventor: Daniel E. Clouatre
-
Publication number: 20220194890Abstract: Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.Type: ApplicationFiled: January 20, 2022Publication date: June 23, 2022Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventors: Daniel E. CLOUATRE, Nimpan BANGUN, DALLAS L. CLOUATRE
-
Patent number: 11219610Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: GrantFiled: March 11, 2020Date of Patent: January 11, 2022Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Publication number: 20210369655Abstract: Provided is a method of treating a subject, including: (i) determining an initial level of blood oxygen saturation in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, wherein HCA is (?)-hydroxycitric acid, a salt thereof, or a derivative thereof, thereby increasing blood oxygen saturation. Provided is a kit including HCA and instructions directing a subject to ingest the HCA if the subject is determined to have unhealthily low blood oxygen saturation. Provided is a method of treating a subject, including: (i) determining an initial level of blood hemoglobin in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, thereby increasing blood hemoglobin.Type: ApplicationFiled: May 25, 2021Publication date: December 2, 2021Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventor: Daniel E. Clouatre
-
Publication number: 20210369657Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.Type: ApplicationFiled: May 25, 2021Publication date: December 2, 2021Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventor: Daniel E. Clouatre
-
Publication number: 20210369656Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.Type: ApplicationFiled: May 25, 2021Publication date: December 2, 2021Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventor: Daniel E. Clouatre
-
Patent number: 11066423Abstract: Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X3(HCA)2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.Type: GrantFiled: May 7, 2020Date of Patent: July 20, 2021Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Daniel E. Clouatre, Nimpan Bangun, Dallas L. Clouatre
-
Publication number: 20210107855Abstract: Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.Type: ApplicationFiled: March 1, 2019Publication date: April 15, 2021Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventors: Daniel E. CLOUATRE, Nimpan BANGUN, DALLAS L. CLOUATRE
-
Publication number: 20200331930Abstract: Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X3(HCA)2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.Type: ApplicationFiled: May 7, 2020Publication date: October 22, 2020Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventors: Daniel E. CLOUATRE, Nimpan BANGUN, DALLAS L. CLOUATRE
-
Publication number: 20200206171Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: ApplicationFiled: March 11, 2020Publication date: July 2, 2020Applicant: Glykon Technologies Group, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Publication number: 20200138767Abstract: A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. CLOUATRE, Daniel E. CLOUATRE
-
Patent number: 10624868Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: GrantFiled: June 25, 2019Date of Patent: April 21, 2020Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Patent number: 10561630Abstract: A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.Type: GrantFiled: October 11, 2017Date of Patent: February 18, 2020Assignee: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre
-
Patent number: 10376483Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: GrantFiled: May 9, 2018Date of Patent: August 13, 2019Assignee: Glykon Technologies Group, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
-
Publication number: 20190175610Abstract: A method of reducing abdominal and subcutaneous fat in the subject as disclosed whereby the subject is administered a formulation comprised of a combination of galantamine and L-carnitine on a daily basis of a period of days.Type: ApplicationFiled: February 26, 2018Publication date: June 13, 2019Applicant: GLYKON TECHNOLOGIES GROUP, LLCInventors: Dallas L. CLOUATRE, Daniel E. CLOUATRE
-
Publication number: 20180256527Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.Type: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Applicant: Glykon Technologies Group, LLCInventors: Dallas L. CLOUATRE, Daniel E. CLOUATRE, Brad J. DOUGLASS
-
Patent number: 10006079Abstract: A method is disclosed for determining the hypoglycemic potential of Momordica charantia (bitter melon) extracts through an in vitro test representative of the range of serum blood sugar typical of normal and diabetic subjects. The in vitro assay provides information on the functional activity of bitter melon extracts for regulating blood glucose uptake in an animal or human.Type: GrantFiled: June 3, 2014Date of Patent: June 26, 2018Assignee: Glykon Technologies Group, LLCInventors: Dallas L. Clouatre, Daniel E. Clouatre